Alsina-Sanchís Elisenda, Figueras Agnès, Lahiguera Alvaro, Gil-Martín Marta, Pardo Beatriz, Piulats Josep M, Martí Lola, Ponce Jordi, Matias-Guiu Xavier, Vidal August, Villanueva Alberto, Viñals Francesc
Program Against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Int J Mol Sci. 2017 Jul 30;18(8):1658. doi: 10.3390/ijms18081658.
There have been no major improvements in the overall survival of ovarian cancer patients in recent decades. Even though more accurate surgery and more effective treatments are available, the mortality rate remains high. Given the differences in origin and the heterogeneity of these tumors, research to elucidate the signaling pathways involved is required. The Transforming Growth Factor (TGFβ) family controls different cellular responses in development and cell homeostasis. Disruption of TGFβ signaling has been implicated in many cancers, including ovarian cancer. This article considers the involvement of TGFβ in ovarian cancer progression, and reviews the various mechanisms that enable the TGFβ signaling pathway to control ovarian cancer cell proliferation. These mechanistic explanations support the therapeutic use of TGFβ inhibitors in ovarian cancer, which are currently in the early phases of development.
近几十年来，卵巢癌患者的总体生存率没有显著提高。尽管有了更精确的手术和更有效的治疗方法，但死亡率仍然很高。鉴于这些肿瘤的起源差异和异质性，需要开展研究以阐明其中涉及的信号通路。转化生长因子（TGFβ）家族在发育和细胞内环境稳定过程中控制着不同的细胞反应。TGFβ信号传导的破坏与包括卵巢癌在内的许多癌症有关。本文探讨了TGFβ在卵巢癌进展中的作用，并综述了使TGFβ信号通路能够控制卵巢癌细胞增殖的各种机制。这些机理解释支持了TGFβ抑制剂在卵巢癌治疗中的应用，目前这些抑制剂正处于开发的早期阶段。
